[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infectionuti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infectionuti":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,92,124,159,189,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643017","early-phase-1-coupled-gentamicin-lactobacillus-rhamnosus-in-nlutd-100643017",false,"NCT07643974","Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD","Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI\u002FD and NLUTD","Inclusion Criteria:\n\n* Neurologic diagnosis\n* ≥18 years old\n* Neurogenic bladder for at least 6 months\n* No USQNB-IC A, B1, or B2 symptoms\n* No currently diagnosed UTI (within 24 hours of initiating instillations)\n* Community dwelling (not in acute hospital setting)\n\nExclusion Criteria:\n\n* Known genitourinary pathology beyond NLUTD (i.e. kidney stones, bladder stones, vesicoureteral reflux, etc.)\n* Use of prophylactic antibiotics or any antibiotics within 2 weeks of beginning instillations\n* Instillation of intravesical agents other than saline bladder wash\n* Immunodeficiency\n* Psychologic or psychiatric conditions influencing the ability to follow instructions\n* Allergy to ampicillin, daptomycin, gentamicin\u002Fgentamycin, or probiotics\n* Participation in another study which could confound results","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The main objective of the proposed research study is to determine in men and women with spinal cord injury\u002Fdisease and neurogenic bladder whether the dose of coupled gentamicin \\& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \\& Lactobacillus instillations.",[26,27,28,29,30,31],"Spinal Cord Injury","Neurogenic Bladder (NB)","Neurogenic Lower Urinary Tract Dysfunction","Multiple Sclerosis","Spina Bifida","Urinary Tract Infection(UTI)",[33,34,35,36,37,38,39],"gentamicin","gentamycin","lactobacillus","spinal cord injury","spinal cord disease","urinary tract infection","neurogenic bladder","NOT_YET_RECRUITING","2026-08-20",{"date":43,"type":44},"2026-08-21","ACTUAL",{"date":46,"type":20},"2026-08",{"date":48,"type":20},"2027-09",{"name":50,"class":51},"Medstar Health Research Institute","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":75,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100624287","phase-3-prediction-and-prevention-of-bloodstream-infections-after-kidney-transplantation-100624287","NCT07407673","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study","PREDICT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Kidney transplant recipient.\n3. Able to provide written informed consent.\n4. ≥1 urine sample with bacteriuria ≥10\\^5 CFU\u002FmL (excluding fungi) within first month post-transplantation.\n\nExclusion Criteria:\n\n1. Known strictures in the esophagus and\u002For obstructions in the gastrointestinal tract including diabetes gastroparesis.\n2. Known hypersensitivity or allergy to β-lactam antibiotics.\n3. Known or suspected genetic metabolism anomalies in the carnitine metabolism, including carnitine transporter defect or organic acidurias such as methylmalonic aciduria or propionic acidaemia.\n4. Individuals of Faroese descent (defined as both biological parents born in the Faroe Islands).\n5. Porphyria.\n6. Current treatment with valproic acid, valproate or other medications liberating pivalic acid.\n7. Current treatment with probenecid.\n8. Current treatment with methotrexate.\n9. Ongoing dialysis one month post-transplantation.\n10. Pregnancy or breastfeeding.",{"count":62,"type":20},180,[64],"PHASE3","Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs). Some of these infections can spread to the bloodstream and cause serious illness, hospitalization, loss of kidney function, or death. Currently, there is no established strategy to prevent these serious bacterial infections in kidney transplant recipients who are at highest risk.\n\nThe PREDICT study is investigating whether a low daily dose of the antibiotic pivmecillinam can reduce the risk of bacterial urinary tract infections and bloodstream infections after kidney transplantation. The study focuses on kidney transplant recipients who have bacteria detected in their urine during the first month after transplantation, as previous research suggests that these patients have a particularly high risk of developing serious infections later.\n\nIn this randomized, double-blind, placebo-controlled trial, 180 adult kidney transplant recipients will be assigned by chance to receive either pivmecillinam or a matching placebo from 1 to 6 months after transplantation. Neither participants nor study staff will know which treatment has been assigned during the study. All participants will continue to receive standard post-transplant care and monitoring.\n\nThe main goal of the study is to determine whether prophylactic pivmecillinam can reduce the occurrence of infections caused by Enterobacterales bacteria, including urinary tract infections and bloodstream infections, during the first 6 months after transplantation. The study will also evaluate the effects of treatment on serious clinical outcomes, safety, quality of life, antimicrobial resistance, and long-term kidney transplant outcomes.\n\nThe study hypothesis is that targeted antibiotic prophylaxis with pivmecillinam in kidney transplant recipients at increased risk of infection will reduce the incidence of Enterobacterales urinary tract infections and bloodstream infections during the high-risk period after transplantation compared with placebo.",[67,68,69,70,71,31,72,73,74],"Kidney Transplant Infection","Bloodstream Infection","Kidney Transplant","Kidney Transplant Recipients","Infection","Urinary Tract Infection Bacterial","Antibiotic Prophylaxis","Bacteriuria",[76,77,38,78,79,80,81],"kidney transplantation","bloodstream infection","antibiotic prophylaxis","pivmecillinam","bacteriuria","Enterobacterales","2026-07-20",{"date":84,"type":44},"2026-07-22",{"date":86,"type":20},"2027-01-01",{"date":88,"type":20},"2041-07",{"name":90,"class":51},"Susanne Dam Nielsen, MD, DMSc",3,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100634680","using-virtual-reality-to-improve-medical-training-100634680","NCT07542834","Using Virtual Reality to Improve Medical Training","Enhancing Osteopathic Medical Education Through Cinematic Virtual Reality","Inclusion Criteria: able to read and speak English, are age 18 years and older, and are a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-\n\nExclusion Criteria: unable to read and speak English, 17 years or younger, and are not a medical student enrolled at the Ohio University Heritage College of Osteopathic Medicine enrolled in the 2025-2026 academic year.\n\n\\-",true,{"count":101,"type":20},100,[103],"NA","As the U.S. population ages, future physicians must be prepared to care for older adults with multiple health conditions and complex needs. This study will test whether cinematic virtual reality (VR)-an immersive, interactive learning tool-is more effective than traditional lectures in helping medical students learn about geriatric care. Students who complete the VR training will experience realistic patient scenarios that show what can go wrong in medical care and learn how to apply osteopathic principles to improve outcomes. Researchers will compare students' performance on a clinical skills assessment and explore their experiences with the VR training. The goal is to determine whether cinematic virtual reality can better prepare students for residency and improve their ability to provide compassionate, high-quality care for older adults.",[106,107,108,109,31,110],"Type 2 Diabetes (T2DM)","Geriatric Syndromes","Disability Hearing","Disability Physical","Delirium Confusional State",[112],"virtual reality, type 2 diabetes, geriatric syndromes, disability, elder abuse and neglect","RECRUITING","2026-04-14",{"date":116,"type":44},"2026-04-21",{"date":118,"type":20},"2026-04-15",{"date":120,"type":20},"2027-06-30",{"name":122,"class":51},"Ohio University",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100610919","hydrogen-peroxide-and-ultraviolet-light-for-disinfecting-surfaces-in-intensive-care-units-100610919","NCT07233837","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units: A Randomized, Controlled, Cluster, Crossover Clinical Trial","Hylight","Inclusion Criteria:\n\n* All patients aged 18 years and older who will be admitted to the participating ICUs\n\nExclusion Criteria:\n\n* Patients under 18 years\n* ICUs that use peroxide hydrogen or ultraviolet light for surface disinfection as part of their protocol",{"count":133,"type":20},5000,[103],"Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes.\n\nThe investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds.\n\nThe primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.",[137,138,139,31,140],"Infection, Hospital","Antimicrobial","Pneumonia Associated With Mechanical Ventilation","Catheter Related Blood Stream Infections",[142,143,144,145,146,147,148,149],"Healthcare associated infections","Antimicrobial use","Intensive care units","pneumonia, ventilator-associated","Catheter-related infections","Urinary tract infections","Hydrogen Peroxide","Ultraviolet light","2026-04-10",{"date":118,"type":44},{"date":153,"type":44},"2026-01-05",{"date":155,"type":20},"2027-03-01",{"name":157,"class":51},"Hospital Israelita Albert Einstein",12,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":123},"100611919","diagnostic-stewardship-intervention-to-reduce-inappropriate-antibiotic-use-for-urinary-tract-infections-in-primary-care-100611919","NCT07246837","Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care","A Randomized Controlled Trial of a Diagnostic Stewardship Intervention to Reduce Inappropriate Antibiotic Use for Urinary Tract Infections in Primary Care","Inclusion Criteria:\n\n* Adults (≥18 years) undergoing urine culture as part of routine outpatient care\n* Able to provide informed consent\n* English- and or Spanish-speaking.\n\nExclusion Criteria:\n\n* Presence of a urinary catheter\n* Inability to read and sign the informed consent\n* Unable to follow study procedures (due to significant visual, auditory, physical or cognitive impairment).",{"count":167,"type":20},252,[103],"Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics.\n\nThe main questions it aims to answer are:\n\n1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates?\n2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions?\n3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural\u002Flinguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.",[31,171,172],"Antimicrobial Stewardship","Primary Care",[174,175,176,177,178,171,172,179],"Urinary Tract Infection","UTI","Inappropriate Antibiotic Use","Diagnostic Stewardship","Antibiotic Resistance","Randomized Controlled Trial","2026-02-11",{"date":182,"type":44},"2026-02-13",{"date":184,"type":44},"2026-01-22",{"date":186,"type":20},"2028-05-31",{"name":188,"class":51},"Baylor College of Medicine",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":123},"100601102","phase-4-antibiotics-for-kidney-transplant-recipients-100601102","NCT07106125","Antibiotics for Kidney Transplant Recipients","Trial of Antibiotic Strategies for Kidney Transplant Recipients","TASK","Inclusion Criteria:\n\n* Must be able to take capsules orally\n* Kidney transplant performed at a UCSF facility within the last 6 months\n* Most recent glomerular filtration rate (GFR) \\>30 mL\u002Fmin\u002F1.73 m2\n* Tolerated initial 6 months of post-transplant TMP-SMX (defined as no intentional periods of TMP-SMX cessation in first 6 months after transplant due to hyperkalemia, allergic reaction, or unexpected\u002Fexcessive neutropenia)\n* Considered \"high risk for UTI\" after kidney transplant, as defined by one or more of the following: (1) Congenital anomaly of kidney\u002Furinary tract as kidney failure etiology, (2) Diagnosis of neurogenic bladder and\u002For use of clean intermittent catheterization and\u002For nightly continuous urinary drainage, (3) Diabetes mellitus (diagnosed either prior to or new-onset after transplant), (4) History of recurrent UTIs as diagnosed by a provider prior to transplant, (5) Occurrence of any UTI in first 6 months after transplant, (6) Delayed graft function (defined as need for dialysis within 7 days of transplant)\n\nExclusion Criteria:\n\n* History of intolerance or allergy to trimethoprim (TMP) and\u002For sulfamethoxazole (SMX)\n* History of UTI due to a TMP-SMX-resistant organism in the first 6 months after transplant\n* Moderate or severe neutropenia (absolute neutrophil count \\\u003C1,000 cells\u002FμL) on most recent bloodwork available at the time of recruitment\n* Uncontrolled hyperkalemia (serum potassium ≥5.0 mEq\u002FL) on most recent bloodwork available at the time of recruitment\n* Provider-determined\u002Fdocumented need for either continuation or discontinuation of TMP-SMX prophylaxis that would preclude the patient's randomization\n* Current pregnancy\n* Incarcerated individuals\u002Fprisoners\n* Inability to provide informed consent or assent, and no legally authorized representative available","29 Years",{"count":199,"type":20},50,[201],"PHASE4","The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.\n\nThe main questions this study is asking are:\n\n* Does TMP-SMX lower the number of UTIs in the first year after transplant?\n* What side effects or problems do participants have while taking TMP-SMX?\n\nResearchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.\n\nParticipants will:\n\n* Take either TMP-SMX or a placebo pill by mouth every day for 6 months\n* Have three visits to touch base with the study team about any issues\n* Complete short monthly online surveys about any symptoms or side effects\n* Share blood and urine test results from their regular transplant clinic visits",[69,31,73,204,205],"Remote Patient Monitoring","Feasibility Pilot Study",[207,208,78,209,210],"kidney transplant","UTI prevention","decentralized trial","remote clinical trial","2025-10-29",{"date":213,"type":44},"2025-10-31",{"date":215,"type":20},"2026-11",{"date":217,"type":20},"2029-01",{"name":219,"class":51},"University of California, San Francisco",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":175,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":227,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":230,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":123},"100607629","emotional-urinary-tract-infection-100607629","NCT07191041","Emotional Urinary Tract Infection","Emotional Distress in Recurrent Urinary Tract Infection","Inclusion Criteria:\n\n* Female patients ≥ 18 years of age\n* Diagnosis of recurrent uncomplicated urinary tract infection (≥2 infections in 6 months or ≥3 infections in one year)\n* Ability to complete questionnaires\n\nExclusion Criteria:\n\n* Patients who had a urologic procedure in the last 3 months\n* History of bladder malignancy\n* History of exposure to pelvic radiation therapy\n* Unwilling or unable to comply with study data collection","FEMALE",{"count":229,"type":20},170,"OBSERVATIONAL","This project proposes a rigorous investigation into the psychological impact of positive urine culture results and recurrent urinary tract infections (UTIs) in women, with a particular focus on Interstitial Cystitis and Bladder Pain Syndrome patients. Interstitial cystitis (IC) or bladder pain syndrome (BPS) is a poorly understood chronic disorder that has an immense impact on quality of life. Stress has been demonstrated to exacerbate bladder symptoms in IC\u002FBPS patients. Because it is often difficult to differentiate IC\u002FBPS symptoms from UTIs, laboratory tests such as urine cultures are often obtained to rule out infectious etiology. Positive lab results can disrupt emotion regulation and impact a variety of health-related coping and outcomes. Chen et al demonstrated in a cohort of 57 IC\u002FBPS patients that the pain index was associated with anxiety mood status and a tendency to develop a sense of hopelessness and helplessness. The impact of positive laboratory results has not been investigated in recurrent UTI patients. Identifying triggers for worsening urinary symptoms is important in the overall management of bladder symptoms therefore it is important to evaluate the impact positive lab results on psychosocial stress level in this population in order provide better patient counseling. By employing validated questionnaires and comprehensive assessments, the study aims to provide evidence-based recommendations for patient counseling and management strategies tailored to address emotional distress and symptom severity. The findings will contribute to improving the overall well-being and quality of life for women affected by recurrent UTIs and associated conditions.",[31,233],"Recurrent Urinary Tract Infections","2025-09-22",{"date":236,"type":44},"2025-09-24",{"date":238,"type":20},"2026-08-28",{"date":240,"type":20},"2027-12-30",{"name":242,"class":51},"Northwell Health"]